S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:SCPH

scPharmaceuticals (SCPH) Stock Forecast, Price & News

$7.12
+0.11 (+1.57%)
(As of 09/29/2023 ET)
Compare
Today's Range
$6.85
$7.15
50-Day Range
$7.00
$8.46
52-Week Range
$3.68
$12.75
Volume
180,358 shs
Average Volume
418,433 shs
Market Capitalization
$255.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.29

scPharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
170.9% Upside
$19.29 Price Target
Short Interest
Bearish
29.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
1.38mentions of scPharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.40) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

536th out of 972 stocks

Pharmaceutical Preparations Industry

249th out of 451 stocks


SCPH stock logo

About scPharmaceuticals (NASDAQ:SCPH) Stock

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

SCPH Price History

SCPH Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Sizing Up scPharmaceuticals
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Maxim Group Keeps Their Buy Rating on scPharmaceuticals (SCPH)
The Latest Analyst Ratings for scPharmaceuticals
scPharmaceuticals (NASDAQ: SCPH)
8-K: scPharmaceuticals Inc.
See More Headlines
Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Company Calendar

Last Earnings
8/10/2023
Today
9/29/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCPH
Fax
N/A
Employees
96
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.29
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+170.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-36,840,000.00
Pretax Margin
-1,209.78%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.11 per share

Miscellaneous

Free Float
34,179,000
Market Cap
$255.32 million
Optionable
Not Optionable
Beta
0.18
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. John H. Tucker (Age 60)
    Pres, CEO, Principal Exec. Officer & Director
    Comp: $912.2k
  • Ms. Rachael Nokes (Age 48)
    CFO & Principal Accounting Officer
    Comp: $496.45k
  • Mr. Michael D. Hassman
    Sr. VP of Technical Operations
  • Katherine Taudvin
    VP of Corp. Affairs & HR
  • Dr. John Mohr Pharm.D.
    Sr. VP of Clinical Devel. & Medical Affairs
  • Steve Parsons
    Sr. VP of Commercial













SCPH Stock - Frequently Asked Questions

Should I buy or sell scPharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCPH shares.
View SCPH analyst ratings
or view top-rated stocks.

What is scPharmaceuticals' stock price forecast for 2023?

6 analysts have issued twelve-month price objectives for scPharmaceuticals' shares. Their SCPH share price forecasts range from $13.00 to $25.00. On average, they predict the company's share price to reach $19.29 in the next year. This suggests a possible upside of 170.9% from the stock's current price.
View analysts price targets for SCPH
or view top-rated stocks among Wall Street analysts.

How have SCPH shares performed in 2023?

scPharmaceuticals' stock was trading at $7.17 at the beginning of the year. Since then, SCPH stock has decreased by 0.7% and is now trading at $7.12.
View the best growth stocks for 2023 here
.

When is scPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SCPH earnings forecast
.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. The firm earned $1.64 million during the quarter, compared to the consensus estimate of $1.55 million.

What other stocks do shareholders of scPharmaceuticals own?
When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

How do I buy shares of scPharmaceuticals?

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $7.12.

How much money does scPharmaceuticals make?

scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $255.32 million. The company earns $-36,840,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com.

This page (NASDAQ:SCPH) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -